Navigation Links
Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Date:5/31/2009

nal linaclotide presentations being made this week at DDW will be:

  • Abstract 236: Global Endpoints in IBS Clinical Trials: Results from a Phase 2b Study of Linaclotide, an oral presentation by Jeffrey Johnston, M.D., F.A.C.P., F.A.C.G. on Sunday, May 31 at 2:30 p.m. CT; McCormick Place, Room E352
  • Abstract 418: Effect of Linaclotide on Quality of Life in Adults with Chronic Constipation: Results from a Phase 2b Study, an oral presentation by Bernard J. Lavins, M.D. on Monday, June 1 at 2:15 p.m. CT; McCormick Place, Room S406A
  • Abstract 1273: Time to Onset of Linaclotide Effect on the Bowel Habits in Patients with Chronic Constipation: Results from a Phase 2b Study, a poster presentation by Jeffrey Johnston, M.D., F.A.C.P., F.A.C.G. on Tuesday, June 2 from 8:00 a.m. to 5:00 p.m. CT; McCormick Place, South Hall

Ironwood and Forest presented the initial analyses from both the IBS-C and CC studies last year.

IBS-C Phase 2b Study Design

This North American-based, randomized, multi-center, double-blind, placebo-controlled, dose-range-finding, parallel-group Phase 2b study was designed to assess the safety, efficacy, and dose response of linaclotide in patients with IBS-C. The primary efficacy endpoint was change from baseline in complete spontaneous bowel movement (CSBM) frequency. The study evaluated the effects of 75, 150, 300, or 600 ug linaclotide or placebo administered orally once daily to adults meeting modified Rome II criteria for IBS-C. Participants underwent a two-week pretreatment (baseline) period before undergoing the 12-week treatment period, followed by a two-week post-treatment period. Daily assessments of bowel habits and symptom severity, and weekly global assessments were performed using an interactive voice response system. During the baseline period patients had to demonstrate <3
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ironwood Announces Linaclotide European Licensing Agreement with Almirall
2. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
3. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
4. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
5. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
8. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, ... President and Chief Executive Officer, will provide an update ... Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... July 27, 2011 Reportlinker.com announces that ... in its catalogue: India ... Till 2016 http://www.reportlinker.com/p0575381/India-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital ...
... 26, 2011 Symmetry Medical Inc. (NYSE: SMA ... orthopaedic device industry and other medical markets, announced today that ... period ending July 2, 2011 before the market opens on ... conference call at 8:00 a.m. ET on Thursday, August 4, ...
Cached Medicine Technology:India Cardiac Catheters and Guidewires - Market Trends Till 2016 2India Cardiac Catheters and Guidewires - Market Trends Till 2016 3Symmetry Medical to Report Second Quarter 2011 Financial Results on August 4, 2011 2
(Date:8/31/2014)... 2014 NutriGold announces that its ... organic fruits and berries, has been approved ... tested, including purity and label claims. , ... Acid from genetically modified and chemically produced corn ... process involves the use of a genetically modified ...
(Date:8/31/2014)... 2014 Market Research Report on ... is a professional and in-depth market survey on ... report firstly reviews the basic information of Cell ... technology. , The report then explores global and ... their product specification, capacity, production value, and market ...
(Date:8/31/2014)... finds that invisible blood in urine may be an early ... for clinicians. , Scientists at the University of Exeter ... age of 60 who had invisible blood in their urine ... bladder cancer. The figure was around half those who had ... of bladder cancer. However, it was still higher than figures ...
(Date:8/31/2014)... August 31, 2014 Adults in the U.S. ... insurance coverage can now use the Quotes Pros website as ... this year can help consumers to find and compare costs ... use of the search tool this year is expected to ... different coverage plans at various price points. The strength of ...
(Date:8/31/2014)... 2014 According to an article posted in ... Times Stronger than Heroin , a new opiate has begun ... more potent than heroin. Known as acetyl fentanyl, this opiate ... many overdoses and emergency room visits among opiate addicts because ... individual might demonstrate the signs of a heroin overdose, they ...
Breaking Medicine News(10 mins):Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 2Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Invisible blood in urine may indicate bladder cancer 2Health News:Life Insurance Quotes Tool Installed for Public Use at New Insurer Portal Website 2Health News:New Street Drug Found to be Much More Powerful Than Heroin 2Health News:New Street Drug Found to be Much More Powerful Than Heroin 3
... The bastion of the diagnostic company, Medlab, seems to ... an Australian Company, which has been the recipient of ... by the district health boards in Auckland, scheduled to ... Australasia Royal College of Pathologists find themselves in a ...
... have known that a woman’s natural hormone levels can ... study from the University of Southern California// (USC)// has ... women varies by ethnicity and race, and may explain ... study appears in the October issue of Cancer Epidemiology, ...
... index (BMI) received lower scores on cognitive tests than middle-aged ... the// October 10, 2006, issue of Neurology, the scientific journal ... investigated the relationships between BMI and cognitive function in 2,223 ... four cognitive tests. The participants, who were between the ages ...
... to assist HIV infection, may aid the fight against malaria, ... already in use to combat HIV is need of the ... new genre of anti-malarial drugs. ,This is indeed ... and also befalling the HIV afflicted lot with uncanny regularity. ...
... holding a world of cures tucked in its many ... right// ingredients needed to nip breast cancer cells in ... discovered in the compound called indole-3-carbinol (I3C), found in ... cancer cells when combined with conventional chemotherapy drugs. By ...
... change in Egypt in spite of the extensive awareness campaigns, ... flu, since May.// ,A woman in the northern ... aggressive form of bird flu virus, H5N1. ,According ... was suffering from high fever and shortness of breath. She ...
Cached Medicine News:Health News:Ethnic Variations in Hormone Levels May Cause Differences in Breast Cancer Risk 2Health News:High BMI Tied to Poor Cognitive Function in Middle-Aged Adults 2
Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
... Olympuss extensive line of affordable, high-quality ... our high-performance light sources to provide optimal ... light weight and durable design give you ... effectively and efficiently. And each is fully-autoclavable ...
Medicine Products: